Literature DB >> 9241066

Role of prolactin in the regulation of macrophages and in the proliferative activity of vascular cells in newly formed and regressing rat corpora lutea.

F Gaytan1, C Morales, C Bellido, E Aguilar, J E Sanchez-Criado.   

Abstract

The proliferative activity of vascular cells and the number of macrophages were studied in corpora lutea of cycling and pregnant rats after prolactin (PRL) administration or depletion with the dopaminergic agonist CB154. Pregnant rats showed a higher proliferative activity of the vascular cells in newly formed corpora lutea than did cycling rats in metestrus. When cycling rats were treated with PRL, the proliferative activity was equivalent to that of pregnant rats. Treatment of pregnant rats with CB154 decreased the proliferative activity of vascular cells to the level in cycling rats. Otherwise, the proliferative activity was not modified in cycling rats after CB154 treatment. This indicates that the increase in the proliferative activity of vascular cells in the corpus luteum of pregnancy was due to the twice-daily PRL surges induced by mating. Treatment of cycling rats with CB154 decreased the number of macrophages in both newly formed and regressing corpora lutea, whereas PRL treatment increased the number of macrophages in regressing corpora lutea. In pregnant rats, treatment with CB154 decreased the number of macrophages in both newly formed and regressing corpora lutea. These results suggest that both the preovulatory and the twice-daily PRL surges regulate the macrophage population in newly formed and regressing corpora lutea.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9241066     DOI: 10.1095/biolreprod57.2.478

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  9 in total

1.  The long and short of the prolactin receptor: the corpus luteum needs them both!

Authors:  Carlos Stocco
Journal:  Biol Reprod       Date:  2012-03-22       Impact factor: 4.285

2.  Pituitary-ovary-spleen axis in ovulation.

Authors:  Oliver R Oakley; Michele L Frazer; CheMyong Ko
Journal:  Trends Endocrinol Metab       Date:  2011-05-18       Impact factor: 12.015

Review 3.  Role of prolactin and vasoinhibins in the regulation of vascular function in mammary gland.

Authors:  Carmen Clapp; Stéphanie Thebault; Gonzalo Martínez de la Escalera
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-19       Impact factor: 2.673

Review 4.  The role of the prolactin/vasoinhibin axis in rheumatoid arthritis: an integrative overview.

Authors:  Carmen Clapp; Norma Adán; María G Ledesma-Colunga; Mariana Solís-Gutiérrez; Jakob Triebel; Gonzalo Martínez de la Escalera
Journal:  Cell Mol Life Sci       Date:  2016-03-29       Impact factor: 9.261

5.  Exogenous estradiol enhances apoptosis in regressing post-partum rat corpora lutea possibly mediated by prolactin.

Authors:  Alicia A Goyeneche; Carlos M Telleria
Journal:  Reprod Biol Endocrinol       Date:  2005-08-30       Impact factor: 5.211

6.  Histological characteristics of the regression of corpora lutea in wistar hannover rats: the comparisons with sprague-dawley rats.

Authors:  Junko Sato; Satomi Hashimoto; Takuya Doi; Naoaki Yamada; Minoru Tsuchitani
Journal:  J Toxicol Pathol       Date:  2014-02-24       Impact factor: 1.628

7.  Effects of indomethacin on ovarian leukocytes during the periovulatory period in the rat.

Authors:  Francisco Gaytán; Concepción Morales; Carmen Bellido; Esteban Tarradas; José Eugenio Sánchez-Criado
Journal:  Reprod Biol Endocrinol       Date:  2003-02-14       Impact factor: 5.211

8.  Effects of deletion of the prolactin receptor on ovarian gene expression.

Authors:  Isabelle Grosdemouge; Anne Bachelot; Aurélie Lucas; Nathalie Baran; Paul A Kelly; Nadine Binart
Journal:  Reprod Biol Endocrinol       Date:  2003-02-06       Impact factor: 5.211

Review 9.  Angiogenesis in the corpus luteum.

Authors:  Hamish M Fraser; Christine Wulff
Journal:  Reprod Biol Endocrinol       Date:  2003-11-10       Impact factor: 5.211

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.